Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.60 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28000044 | 1.00 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CNISCHMTOR | |
| SCHEMBL30471629 | 0.90 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CNISCHMTOR | |
| SCHEMBL698493 | 0.85 | ADRA2A (0.58) | ADRA2AADRA2BADRA2CNISCHMTOR | |
| SCHEMBL953558 | 0.83 | ADRA2A (0.48) | ADRA2AADRA2BADRA2CNISCHMTOR | |
| SCHEMBL697119 | 0.83 | NISCH (0.52) | ADRA2AADRA2BADRA2CNISCHMTOR | |
| SCHEMBL14576492 | 0.81 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CNISCHMTOR | |
| SCHEMBL12716698 | 0.81 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CNISCHTAAR1 | |
| SCHEMBL697579 | 0.81 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CNISCHTAAR1 | |
| SCHEMBL3526225 | 0.81 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CNISCHTAAR1 | |
| SCHEMBL29046781 | 0.81 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CNISCHMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0266989-A2 | Dihydropyridine anti-allergic and anti-inflammatory agents | Pfizer Limited (GB) | 1988-05-11 | — | — | EP | claimed |
| CN-117321103-A | Chloroprene polymer, chloroprene polymer composition, vulcanized molded body, and roll | 电化株式会社 | 2023-12-29 | — | — | CN | disclosed |
| CN-117321102-A | Chloroprene polymer, chloroprene polymer composition, vulcanized molded body, and roll | 电化株式会社 | 2023-12-29 | — | — | CN | disclosed |
| CN-116323785-A | Rubber composition, sulfide, and vulcanized molded article | 电化株式会社 | 2023-06-23 | — | — | CN | disclosed |
| CN-116323784-A | Rubber composition, sulfide, and vulcanized molded article | 电化株式会社 | 2023-06-23 | — | — | CN | disclosed |
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| EP-1981853-B1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875645-B2 | 2-(2-cyclopropyl-benzyl)-4,5-dihydro-1H-imidazole; depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders | HOFFMAN-LA ROCHE INC. (US) | 2011-01-25 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-7148214-B1 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-12 | — | — | US | disclosed |
| US-7087595-B2 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-08 | — | — | US | disclosed |
| EP-1144411-B1 | ANTIHISTAMINIC SPIRO COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050026901-A1 | Antiallergens; vision disorders | JANSSENS FRANS EDUARD (BE) | 2005-02-03 | — | — | US | disclosed |
| EP-1144411-A1 | ANTIHISTAMINIC SPIRO COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000037470-A1 | ANTIHISTAMINIC SPIRO COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
| US-5624947-A | Phenyl derivatives useful as tachykinin antagonists | MERCK, SHARP & DOHME LTD. (GB) | 1997-04-29 | — | — | US | disclosed |
| WO-1994014767-A1 | PHENYL DERIVATIVES USEFUL AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026901-A1 | Antiallergens; vision disorders | UACA, LTB4R, HLA-B | ADRA2A 415/4885ADRA2B 210/4885ADRA2C 888/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ADRA2A 456/4885ADRA2B 317/4885ADRA2C 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.